

## **PHARMACY AND THERAPEUTICS (P&T) COMMITTEE**

**August 9, 2023**

The meeting of the Pharmacy and Therapeutics (P&T) Committee of the North Carolina State Health Plan for Teachers and State Employees (the Plan) was called to order at 6:31 P.M. (EST) on Wednesday, August 9, 2023, via webinar, accessible to the public through the Plan's website. Quorum was present.

### **MEMBERS PRESENT:**

John Anderson, MD, MPH, Associate Professor, Duke Family Medicine and Community Health  
Jennifer Burch, PharmD, CDE, Owner, Central Compounding Center  
Peter Robie, MD, General Internist, Wake Forest Baptist Community Physicians  
Phil Seats, RPh, Retired Pharmacist  
W. Russell Laundon, PharmD, Pharmacist, Director of Pharmacy Integration, UNC Health Care

### **MEMBERS ABSENT:**

Sheel Solomon, MD, Dermatologist, Preston Dermatology and Skin Surgery  
Ghassan Al-Sabbagh, MD, Gastroenterologist/Hepatologist, Gastroenterology & Hepatology Consultants  
Sundar Ramalingam, MD, Oncologist, Duke Cancer Center  
David Konanc, MD, Neurologist, Raleigh Neurology Associates  
Laura Rachal, MD, Pediatric Infectious Diseases Specialist, University of North Carolina Hospitals

### **PLAN & VENDOR STAFF:**

Jenny Vogel, PharmD, Sr. Clinical Pharmacist, State Health Plan  
Sam Watts, Interim Executive Director, State Health Plan  
Dale Folwell, CPA, State Treasurer  
Caroline Smart, Sr. Director, Plan Integration, State Health Plan  
Sonya Dunn, MPA, BSPH, RN, Sr. Pharmacy Benefits Program Manager, State Health Plan  
Renée Jarnigan, RPh, Clinical Advisor, CVS Health

### *Welcome*

The Chairperson welcomed the Committee members and guests to the webinar and performed roll call. Dr. Vogel welcomed and acknowledged new committee member Dr. Laundon.

### *Conflict of Interest Statement*

The Chairperson requested that the P&T Committee members review the agenda, which was distributed prior to the meeting, and disclose any actual or potential conflicts of interest with any item on the agenda. No conflicts of interest were noted.

### *Old Business*

The Chairperson asked the P&T Committee members to review the May 10, 2023 P&T Committee Meeting minutes, which were distributed prior to the meeting. There were no additions or corrections to the minutes, so they were approved as is.

The Chairperson asked the P&T Committee members to review the proposed amendments to the Bylaws, which were distributed prior to the meeting. Without objection the Bylaws were approved as is.

### *Formulary Updates*

Ms. Jarnigan presented CVS Caremark's Quarterly Formulary Updates, effective October 1, 2023. This included additions to the formulary, utilization management criteria, drug removals, and tier movements.

Ms. Jarnigan presented proposed formulary additions including line extensions. The four formulary additions are as follows: QUVIVIQ, FYLNETRA, NYVEPRIA, and OBIZUR. The fourteen line extensions are as follows: methylphenidate tab er (18mg, 27mg, 36mg, and 54mg), levofloxacin sol 1.5%, GRALISE TAB (450mg, 750mg and 900mg), NAMZARIC CAP PACK, AKYNZEO INJ 235-0.25, PERTZYE CAP 24000U, PODIAPN CAP, PRECEDEX INJ 1000/250, TEMBEXA TAB 100MG; SUS 10MG/ML, ZEJULA TAB (100 MG, 200 MG and 300 MG), ZEPOSIA CAP STR KIT, AMJEVITA INJ 10/0.2ML, KALYDECO GRA 13.4 MG, TRIKAFTA PAK (59.5 MG and 75 MG).

Ms. Jarnigan and Dr. Vogel identified seven new molecular entities that were being removed from CVS's New-to-Market block and would be available as covered products, along with any utilization management policies that went along with the new products. The new molecular entities being added to the formulary are as follows: VOWST, REZZAYO, POLIVY, KRAZATI, SOTYKTU, VTAMA and ZORYVE.

The Committee also approved proposed utilization management for the new entities including SGM for POLIVY, SGM and Specialty QL for VOWST, KRAZATI, and SOTYKTU, also PA and QL for ZORYVE and VTAMA.

There was no opposition from the Committee members, so the formulary additions and line extensions with any associated utilization management were approved as presented.

Dr. Anderson presented MOUNJARO to the Committee. There was discussion among committee members about MOUNJARO and GLP-1 medications and their role within the State Health Plan. MOUNJARO was not voted to be added at this time.

Ms. Jarnigan then explained the Utilization Management strategies including the Dermatologic Strategy, PA for Topical Vitamin D Analogs, Revised QL/Custom post-limit PA for Temazepam and the Weight Loss Management Bundle. Dr. Anderson requested clarification on the Weight Management Bundle and was satisfied with the response from Ms. Jarnigan.

There was no opposition from the Committee members, so all Utilization Management additions were approved as presented.

Ms. Jarnigan then explained that the Plan has a formulary exclusion exception process that is available to support Plan members who, per their provider, have a medical necessity to remain on an excluded drug. Ms. Jarnigan then reviewed the following two products that will be excluded from the formulary starting on the effective date: diclofenac powder and ZIEXTENZO.

All products being removed have therapeutic alternatives or generic equivalents that are covered as preferred products on the Plan's custom formulary. There was no opposition from the Committee members, so these product exclusions were approved as presented.

Ms. Jarnigan then identified one branded product, VYVANSE, which will have a change in tier from preferred to non-preferred. The generic product lisdexamfetamine is set to launch in August 2023, as such this tier change will be implemented once the generic product is available.

There was no opposition from the Committee member, so the formulary uptier was approved as presented.

#### *Adjourn*

On behalf of Treasurer Folwell, Mr. Watts thanked the Committee for their service. The Chairperson then informed the Committee that the next meeting would be held on October 11, 2023 at 6:30 P.M. via webinar. The meeting was adjourned at approximately 8:02 P.M. (EST)